In a report released today, Raju Prasad from William Blair maintained a Buy rating on Poseida Therapeutics (PSTX). The company’s shares closed last Monday at $10.75.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 11.2% and a 52.3% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.
Poseida Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.00.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors.
